BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Monday, February 9, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Feb. 19, 2003
View Archived Issues
French team reports inhibitors of atheroma formation
Read More
CV Therapeutics claims adenosine A2B antagonists for asthma and other uses
Read More
Orally active DHFR inhibitors discovered at Essential Therapeutics
Read More
Dong Wha reports novel agents for hepatitis B and C infection
Read More
New antidiabetic PTP inhibitors in Novo Nordisk pipeline
Read More
Aventis claims novel factor VIIa inhibitors
Read More
Japanese researchers identify novel peptides with anti-HIV activity
Read More
Tucaresol reported to restore immune function in HAART-treated HIV patients
Read More
Good long-term efficacy profile reported for abacavir combined with lamivudine
Read More
HIV susceptibility to tipranavir maintained following tipranavir/ritonavir therapy
Read More
Humanized MAbs targeting CEA available for licensing from NIH
Read More
Atazanavir in healthy subjects and HIV-infected patients
Read More
Atugen identifies novel cancer target
Read More
Atugen and metaGen sign target validation agreement
Read More
Kyowa Hakko establishes U.S. antibody business
Read More
Patient enrollment completed in phase II ALS study of EHT-0201
Read More
Animal toxicology program completed for systemic Reolysin
Read More
Development of oral botulinum toxin vaccine commences at DOR BioPharma
Read More
Further milestone payment made under D-63153 development agreement
Read More
Medivir presents 2002 summary
Read More
Deramciclane will not be developed for GAD indication
Read More
AZD-3582 does not reach primary endpoint in a phase II study
Read More
Superior survival compared to Atgam not achieved in GvHD patients treated with ABX-CBL
Read More
New phenylisoxazolines active against resistant Gram-positive pathogens
Read More
